Should we clean up the reputation of "dirty drugs"?

Can J Physiol Pharmacol. 2012 Oct;90(10):1333-4. doi: 10.1139/y2012-110. Epub 2012 Sep 28.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Dietary Supplements / adverse effects
  • Drug Design*
  • Drugs, Investigational / adverse effects*
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Molecular Targeted Therapy* / adverse effects
  • Piperazines / adverse effects
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Purines / adverse effects
  • Purines / pharmacology
  • Purines / therapeutic use
  • Sildenafil Citrate
  • Sulfones / adverse effects
  • Sulfones / pharmacology
  • Sulfones / therapeutic use
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / pharmacology
  • Vasodilator Agents / therapeutic use

Substances

  • Drugs, Investigational
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate